Edwards to buy back $250m shares
This article was originally published in Clinica
Edwards Lifesciences is to acquire up to $250m of its outstanding stock in a newly authorised share buy-back programme. The Irvine, California-based cardiovascular firm said the timing and extent of the repurchase will depend on market conditions, corporate requirements and other factors. In the first half of this year, the company spent $235m repurchasing 4.6 million shares. As of June 30 2008, the company had approximately 56.2 million shares outstanding.